Reuters logo
BRIEF-Immune Pharmaceuticals' Oncology subsidiary, Cytovia Inc. Provides update to proposed pint pharma transaction
2017年6月29日 / 下午2点47分 / 4 个月前

BRIEF-Immune Pharmaceuticals' Oncology subsidiary, Cytovia Inc. Provides update to proposed pint pharma transaction

June 29 (Reuters) - Immune Pharmaceuticals Inc

* Immune pharmaceuticals’ oncology subsidiary, cytovia inc. Provides update to proposed pint pharma transaction: substantial agreement reached on material terms of the licensing and commercialization of ceplene® in latin america

* Immune pharmaceuticals inc - substantial agreement reached on material terms of licensing and commercialization of ceplene® in latin america

* Immune pharmaceuticals inc - parties currently anticipate that they will execute a definitive licensing agreement within next five to seven business days

* Immune pharmaceuticals inc - parties have agreed to enter into definitive agreement related to pint’s commitment to invest $4 million into cytovia

* Immune pharmaceuticals inc - “plan to pursue approval of ceplene in united states based on previously announced global overall survival study, remain”

* Immune pharmaceuticals inc - massimo radaelli, executive chairman of pint will join board of directors of cytovia following completion of investment

* Immune pharmaceuticals - “plan is to commercialize ceplene in combination with low dose il-2 in all markets that accept european registration dossier as a basis for approval” Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below